American Academy of Family Physicians

Printer-friendly version

Share this on AAFP Connection

Share this page

FDA Fighting for Authority to Regulate Electronic Cigarettes

Appeals Court Order Stays Lower Court Ruling in Favor of e-Cigarette Distributors

By News Staff

A U.S. Court of Appeals ruling reinstates the FDA's authority -- at least temporarily -- to stop e-cigarettes from entering the country after a lower court ruled that the agency does not have the authority to regulate electronic cigarettes, even though Congress granted the agency the power to regulate tobacco products in 2009.
Stock photo of electronic cigarette
The FDA filed the appeal (15-page PDF; About PDFs) after a U.S. District Court judge granted an injunction (2-page PDF; About PDFs) on Jan. 14 that blocked the FDA from stopping electronic cigarettes from entering the country. The appeals court granted a stay (1-page PDF; About PDFs) of the district court's injunction, pending an appeal. The stay reinstates the FDA's authority.

District Court Judge Richard Leon said in the Jan. 14 ruling that the Family Smoking Prevention and Tobacco Control Act passed last year does give the agency the authority to regulate "any product made or derived from tobacco that is intended for human consumption." That could include e-cigarettes, which contain nicotine extracted from tobacco.

FDA officials, however, say they would prefer to regulate e-cigarettes as drug delivery devices rather than as tobacco products because treating e-cigarettes as the former would give the agency far broader control, including the ability to block importation of the devices and their components.

The agency said in its appeal that it has regulated nicotine products, including nicotine patches, for years under the drug and device provisions of the Food, Drug and Cosmetic Act, or FDCA. The agency argued that tobacco legislation enacted last year "expressly excludes from the definition of 'tobacco product' any article that is a drug, device or combination product under the FDCA, and provides that such articles shall be subject to regulation under the pre-existing FDCA provisions."

An agency spokesperson declined to comment on the case, which is ongoing.

According to court records, the dispute between the FDA and e-cigarette distributors started in September 2008 -- before the tobacco legislation passed -- when the agency put a hold on two shipments of e-cigarettes at Los Angeles International Airport. A month later, FDA officials issued notices of detention on the grounds that shipments belonging to Smoking Everywhere Inc. -- one of the companies that later sued the FDA -- appeared to be "adulterated, misbranded or otherwise in violation" of the FDCA.

In July 2009, the FDA issued a warning about e-cigarettes to consumers and physicians after the Division of Pharmaceutical Analysis in the agency's Center for Drug Evaluation and Research said samples from the products had detectable levels of known carcinogens and toxic chemicals.

Manufacturers have touted the smokeless products, which are battery-operated devices that turn nicotine and other chemicals into a vapor that is inhaled by the user, as safer than conventional cigarettes. However, public health officials have countered that the products have not been adequately tested and should not be marketed to young people.

Share this on AAFP Connection

Health of the Public

CDC to Fund 2D Vaccine Barcoding Pilot

2012 Immunization Schedules Reflect Multiple Changes

Study: Cognitive Decline Detected in Middle-aged Adults

CDC Toolkit Can Help Clinicians Fight Norovirus Infection

Patient-Centered Care Linked to Lower Mortality

Study: Inappropriate Cancer Screenings Continue

Novartis Manufacturing Plant Closes After Drug Mix-ups

FDA Announces Classwide REMS for TIRF Medications

New Infants' Acetaminophen Products Hit Store Shelves

Avoid Environmental Factors Linked to Breast Cancer

Risk for Thrombosis Prompts REMS for Rivaroxaban

Common Drugs Implicated in Most Emergency Hospitalizations

CDC Launches Campaign for Child Medication Safety

HHS Blocks Expanded OTC Access to Plan B

Push Is On to Vaccinate Pregnant, Postpartum Women

FDA Committee Votes to Broaden PCV13 Indication

AAFP Foundation Program Aims to Fight Chronic Disease

NIAAA Alcohol Screening Guide Targets Teens

Walgreens, AAFP Launch Flu Vaccine Pilot in Five States

Helping Patients Quit Smoking Starts With a Question

Trilipix Efficacy in Question, Says FDA

USPSTF Addresses Skin Cancer, Obesity, Cervical Cancer Screening

AAFP Endorses ACP Guideline on ED

ACIP Recommends Expanded HPV, Hepatitis B Vaccination

Bacterial Contamination Spurs Nasal Spray Recall

CDC Renews Call for PCV13 Vaccination

USPSTF Recommends Against PSA Screening

AAFP Supports HHS' Million Hearts Initiative

FDA Phases Out Primatene Mist Inhalers

AHRQ Guides Explain Benefits, Risks of GERD Treatments

Tar Wars Winner Gives Back

Office Champions Project Nets Smoking Cessation Gains

Multiple Lots of Oral Contraceptives Recalled

New Vaccine Review Finds Few Adverse Events

HPV Vaccination Rates Still Lag, Says CDC

Renal Injury Prompts Reclast Label Changes

High-dose Citalopram Linked to Abnormal Heart Rhythms

AHRQ Sleep Apnea Guides Review Diagnosis, Management

Board Chair Spotlights Breadth of Family Medicine Training

USPSTF Softens Stance on Bladder Cancer Screening

HHS Expands Coverage for Women's Preventive Services

Birth Defects Linked to Fluconazole Prompt FDA Warning

FDA Warns of Mixing Certain MAOIs, Serotonergic Drugs

Oseltamivir Concentration Revised to Ensure Accurate Dosing

Teledermatology Project Aids Underserved Patients

New Chantix Warnings Cite Cardiovascular Risk

Pertussis Outbreaks Lead to CDC Alert on PCR Testing